BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10499623)

  • 1. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
    Buller RE; Shahin MS; Holmes RW; Hatterman M; Kirby PA; Sood AK
    Am J Obstet Gynecol; 2001 Apr; 184(5):891-902; discussion 902-3. PubMed ID: 11303196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
    Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance].
    You Z; Guo Y; Wen H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):660-3. PubMed ID: 9387525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
    Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
    Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
    Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
    J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
    Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
    Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutation is a common genetic event in ovarian carcinoma.
    Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
    Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
    Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
    Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.